GleamWall
中文EN

CNSP CNS Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1729427 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-22.3%
TTM EPS YoY-102.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-124.8%
ROA-106.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.65x
Interest coverage-1,031.22x

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-13.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$890,000$1.20M$3.54M$3.17M$2.20M$1.17M$3.24M$1.50M
SG&A expense$1.77M$1.50M$1.43M$2.82M$1.06M$1.24M$1.09M$1.70M
Operating income-$2.67M-$2.70M-$4.98M-$5.99M-$3.25M-$2.41M-$4.34M-$3.20M
Interest expense$3,000$4,000$6,111$2,721$2,000$4,000$6,208$2,774
Net income-$2.50M-$2.59M-$4.94M-$5.96M-$3.22M-$2.38M-$4.30M-$3.18M
EBITDA-$2.67M-$2.69M-$4.97M-$5.99M-$3.25M-$2.41M-$4.34M-$3.20M
EPS (basic)-0.24-0.38-7.30—-5.76-6.42-18.93—
EPS (diluted)-0.24-0.38-7.30—-5.76-6.42-18.93—
Weighted avg. shares (diluted)10.61M6.84M676,172—558,868370,127227,220—
Balance sheet
Cash & equivalents$17.21M$19.98M$2.95M$7.20M$9.86M$12.13M$13.05M$6.46M
Current assets$18.05M$21.92M$4.08M$8.10M$11.39M$14.14M$13.72M$8.66M
PP&E, net$14,000$15,000$22,014$18,000$3,107$3,804$4,905$6,005
Total assets$18.06M$21.94M$4.65M$8.62M$11.87M$14.51M$13.75M$8.70M
Current liabilities$2.36M$3.74M$4.58M$4.10M$1.96M$1.38M$2.78M$2.52M
Total liabilities$2.36M$3.74M$4.58M$4.10M$1.96M$1.38M$2.78M$2.52M
Shareholders' equity$15.71M$18.20M$71,000$4.52M$9.91M$13.12M$10.97M$6.18M
Shares outstanding1.48M1.46M811,449632,516574,580504,4132.94M117,796
Cash flow statement
Operating cash flow-$2.77M-$3.54M-$4.65M-$3.05M-$2.17M-$5.34M-$3.24M-$5.47M
Capital expenditure$0$3,821$6,179$18,175$0$0$0$4,188
Free cash flow-$2.77M-$3.54M-$4.65M-$3.07M-$2.17M-$5.34M-$3.24M-$5.48M
Investing cash flow$0-$3,821-$6,179-$18,175$0$0$0-$4,188
Financing cash flow$0$20.58M$404,660$406,872-$92,000$4.43M$9.83M$4.96M
Depreciation & amortization$0$11,132$1,868$1,020$1,000$1,101$1,100$985
Stock-based compensation$25,000$2,000$2,555$85,068$19,000$22,000$62,367$129,900

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.